Autotransplantation of bone marrow-derived stem cells as a therapy for neurodegenerative diseases
- PMID: 17554511
- DOI: 10.1007/978-3-540-68976-8_10
Autotransplantation of bone marrow-derived stem cells as a therapy for neurodegenerative diseases
Abstract
Neurodegenerative diseases are characterized by a progressive degeneration of selective neural populations. This selective hallmark pathology and the lack of effective treatment modalities make these diseases appropriate candidates for cell therapy. Bone marrow-derived mesenchymal stem cells (MSCs) are self-renewing precursors that reside in the bone marrow and may further be exploited for autologous transplantation. Autologous transplantation of MSCs entirely circumvents the problem of immune rejection, does not cause the formation of teratomas, and raises very few ethical or political concerns. More than a few studies showed that transplantation of MSCs resulted in clinical improvement. However, the exact mechanisms responsible for the beneficial outcome have yet to be defined. Possible rationalizations include cell replacement, trophic factors delivery, and immunomodulation. Cell replacement theory is based on the idea that replacement of degenerated neural cells with alternative functioning cells induces long-lasting clinical improvement. It is reasoned that the transplanted cells survive, integrate into the endogenous neural network, and lead to functional improvement. Trophic factor delivery presents a more practical short-term approach. According to this approach, MSC effectiveness may be credited to the production of neurotrophic factors that support neuronal cell survival, induce endogenous cell proliferation, and promote nerve fiber regeneration at sites of injury. The third potential mechanism of action is supported by the recent reports claiming that neuroinflammatory mechanisms play an important role in the pathogenesis of neurodegenerative disorders. Thus, inhibiting chronic inflammatory stress might explain the beneficial effects induced by MSC transplantation. Here, we assemble evidence that supports each theory and review the latest studies that have placed MSC transplantation into the spotlight of biomedical research.
Similar articles
-
Bone-marrow-derived mesenchymal stem cell therapy for neurodegenerative diseases.Expert Opin Biol Ther. 2009 Dec;9(12):1487-97. doi: 10.1517/14712590903321439. Expert Opin Biol Ther. 2009. PMID: 19821796 Review.
-
Immunomodulation and neuroprotection with mesenchymal bone marrow stem cells (MSCs): a proposed treatment for multiple sclerosis and other neuroimmunological/neurodegenerative diseases.J Neurol Sci. 2008 Feb 15;265(1-2):131-5. doi: 10.1016/j.jns.2007.05.005. Epub 2007 Jul 3. J Neurol Sci. 2008. PMID: 17610906 Review.
-
Gene therapy progress and prospects: stem cell plasticity.Gene Ther. 2005 Aug;12(16):1229-34. doi: 10.1038/sj.gt.3302571. Gene Ther. 2005. PMID: 15973440 Review.
-
Bone marrow-derived mesenchymal stem cells for the treatment of ischemic stroke.J Clin Neurosci. 2009 Jan;16(1):12-20. doi: 10.1016/j.jocn.2008.05.006. Epub 2008 Nov 18. J Clin Neurosci. 2009. PMID: 19017556 Review.
-
Increased proliferation of human synovial mesenchymal stem cells with autologous human serum: comparisons with bone marrow mesenchymal stem cells and with fetal bovine serum.Arthritis Rheum. 2008 Feb;58(2):501-10. doi: 10.1002/art.23219. Arthritis Rheum. 2008. PMID: 18240254
Cited by
-
Tackling the physiological barriers for successful mesenchymal stem cell transplantation into the central nervous system.Stem Cell Res Ther. 2013 Aug 22;4(4):101. doi: 10.1186/scrt312. Stem Cell Res Ther. 2013. PMID: 23998480 Free PMC article. Review.
-
Stem cell therapies in age-related neurodegenerative diseases and stroke.Ageing Res Rev. 2017 Mar;34:39-50. doi: 10.1016/j.arr.2016.11.002. Epub 2016 Nov 19. Ageing Res Rev. 2017. PMID: 27876573 Free PMC article. Review.
-
Mesenchymal stem cells stimulate endogenous neurogenesis in the subventricular zone of adult mice.Stem Cell Rev Rep. 2011 Jun;7(2):404-12. doi: 10.1007/s12015-010-9190-x. Stem Cell Rev Rep. 2011. PMID: 20830611
-
Preliminary results of cord blood mononuclear cell therapy for multiple system atrophy: a report of three cases.Med Princ Pract. 2014;23(3):282-5. doi: 10.1159/000354051. Epub 2013 Aug 13. Med Princ Pract. 2014. PMID: 23948955 Free PMC article.
-
Preclinical studies on mesenchymal stem cell-based therapy for growth plate cartilage injury repair.Stem Cells Int. 2011;2011:570125. doi: 10.4061/2011/570125. Epub 2011 Jul 26. Stem Cells Int. 2011. PMID: 21808649 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical